A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors

Disease Area: Solid Tumors  
Investigator: Dennis Slamon  
Institution: University of California, Los Angeles  
CIRM Grant: DR3-07067  
Award Value: $5,683,693  
Trial Sponsor: University Health Network, Toronto  
Trial Stage: Phase 1  
Trial Status: Recruiting  
Targeted Enrollment: 48  
ClinicalTrials.gov ID: NCT01954316

Details:
Solid tumors are the most prevalent form of cancer, and are a major cause of death worldwide. A team at UCLA is testing a drug for the treatment of cancer that works by blocking PLK4, a protein that is important in regulating cell growth, division and death. This protein is important for the survival of the cancer stem cell as well as the rest of the cells in a tumor. It is hypothesized that blocking this protein from working in the tumor may stop or even shrink tumor growth.

Design:
Dose escalation and expansion.

Goal:
Determination of maximum tolerated dose and recommended Phase 2 dose. Safety. PK. Efficacy in solid cancers.

Updates:
Ongoing.

Contact Trial Sponsor

Source URL: https://www.cirm.ca.gov/clinical-trial/phase-i-dose-escalation-and-expansion-clinical-trial-novel-first-class-polo-kinase-4